Savara (NASDAQ:SVRA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Savara (NASDAQ:SVRA) released its quarterly earnings results on Thursday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02), Zacks reports. The company had revenue of $0.27 million for the quarter.

Savara Price Performance

SVRA opened at $2.91 on Friday. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The company’s 50-day moving average price is $2.72 and its 200 day moving average price is $3.26. Savara has a fifty-two week low of $2.26 and a fifty-two week high of $5.34. The firm has a market cap of $499.41 million, a price-to-earnings ratio of -6.77 and a beta of 0.60.

Analyst Ratings Changes

SVRA has been the topic of several recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of Savara in a report on Thursday, December 19th. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Savara in a research report on Friday. Finally, Wells Fargo & Company assumed coverage on shares of Savara in a research report on Friday, December 20th. They set an “overweight” rating and a $8.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $8.83.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.